The Boxed Warning is Gone: Why Your Drug Listing is Now Non-Compliant (Immediate SPL Resubmission Required)

FDA Just Changed HRT Labeling: 5 Action Items Regulatory Teams Must Complete in 90 Days.

The FDA has just announced a landmark policy change: the class-wide “black box” (boxed) warnings will be removed from estrogen-containing menopausal hormone therapy (HRT) products in the United States. This signals not only new regulatory expectations but a realignment of drug labeling to fit contemporary scientific evidence and risk-benefit analysis.

Key Labeling Changes Mandated by FDA

The following table summarizes the required regulatory changes that must be reflected in the product labeling and subsequent electronic submissions:

Category	Regulatory Change / Action Required	FDA Logic
Boxed Warning Removal	Remove language related to cardiovascular disease, breast cancer, and probable dementia from the Boxed Warning3.	Corrects outdated risk framing from early WHI-era interpretations.
Boxed Warning Retained	Retain the Boxed Warning for endometrial cancer in systemic estrogen-alone products (where a uterus is present)4.	Retains necessary warning based on current evidence.
Dosing Guidance	Remove the vague guidance to use the “lowest effective dose for the shortest time” from the Boxed Warning context5.	Replaces outdated language for clearer medical guidance.
Label Content Added	Add guidance for initiating therapy in women under 60 years old or within 10 years of menopause onset6.	Reflects updated benefit/risk assessment based on new population cohort data.
Vaginal Products	Simplify safety information and tailor risks relevant to local use (versus systemic exposure)7.	Clarifies risks for local, non-systemic use.

Immediate 5-Step Compliance Strategy

For regulatory teams, this is a complex, coordinated update across multiple systems.

1. Labeling & Text Authoring: Author updated labeling text, ensuring alignment with the new FDA guidance and the removal of Boxed Warning elements.

2. SPL XML Updates (CRITICAL): Because labeling changes, SPL XML must be updated. This involves creating revised XML files that reflect the updated package insert and removal of Boxed Warning elements.

3. Drug Listing Re-Submission: Once the SPL file is validated, the revised listing must be resubmitted to FDA’s electronic system. Failure can lead to inactive listings and import screening issues.

4. Promotional Review: All marketing claims, professional materials, or digital content referencing the old warning must be updated or withdrawn.

5. Compliance Documentation: Maintain a full record of the change control process, justification for revisions, and internal approval routing for future inspections.

Timeline and Next Steps

The FDA expects all label revisions and supplement filings to be completed as soon as possible. There is no fixed grace period, but delayed compliance could result in warning letters, import holds, or delayed U.S. market access.

• Action: Check for updated FDA guidance via the official FDA website and work closely with your US Agent for any Q&A sessions or ad hoc teleconferences with the agency.

Compliance Strategy: How Axentra Can Help

Axentra Global Pharma Compliance supports foreign manufacturers, importers, and regulatory professionals with end-to-end solutions for FDA label changes and U.S. market strategy.

• Regulatory Intelligence: Track live updates on compliance deadlines and link your global change control system to capture FDA/EMA/ROW developments.

• US Agent Coordination: Use real-time cross-border collaboration with your US Agent to streamline all FDA interactions and submissions. Learn more about our U.S. Agent Services

Trusted U.S. Agent for Regulatory Clarity and Global Confidence.

For a confidential assessment of your product portfolio or to ensure your regulatory updates are accurate, timely, and inspection-ready, connect with our experts

#FDALabelChange #HRTCompliance #RegulatoryAffairs #USAgent #PharmaCompliance #AxentraGlobal